Advanced Drug Delivery, Pharmaceutical Science, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
Pharmaceutical Technology & Development, AstraZeneca, Gothenburg, Sweden.
Eur J Pharm Sci. 2019 Feb 1;128:128-136. doi: 10.1016/j.ejps.2018.11.028. Epub 2018 Nov 29.
AZ3411 was selected as a lead compound for the treatment of Inflammatory Bowel Disease (IBD). The present research aimed to perform an early pharmaceutical assessment of this NK antagonist candidate focusing on the challenging solid-state part of the evaluation. X-ray powder diffraction (XRPD), hot stage XRPD and microscopy, differential scanning calorimetry, thermogravimetrical analysis measurements, nuclear magnetic resonance spectroscopy and liquid chromatographic analysis were used to characterize AZ3411. The amorphous, free base form of AZ3411 was transformed to a poorly crystalline material by salt formation using maleic acid. Suspensions of the poorly crystalline form (type A), prepared in various solvents, exhibited phase transformation on storage. Some precipitate was identified as a new, more crystalline form (type B) of the maleate salt of AZ3411. Also, a third crystalline form was observed at high temperatures (type C). AZ3411 maleate type A, maleate type B and amorphous, free base form was stored in 40 °C/75% relative humidity (RH), 60 °C and 80 °C for three months. Form B was found to be the most chemically stable at all conditions. After three months at 40 °C/75%RH, both type A and type B had transformed to the anhydrous type C. Moreover, type B was transformed to form C at 60 °C and 80 °C, while type A remained unchanged. These results, together with the loss of water with temperature, suggest that type B is a hydrate. The relative stability between the hydrate type B and anhydrous type C depend on humidity and temperature. Moreover, the photosensitivity of maleate type A, maleate type B and amorphous free base has been investigated under three different illumination conditions. In similarity to the previous study, Form B was the most chemically stable form. However, after completion the study, at the highest energy conditions (765 W/m, 250-800 nm), the crystalline type B had transformed to type C, while type A had lost in crystallinity. A similar photostability study was performed on solutions of pH 1 and pH 7. The degradation pattern was similar for the two pHs but appeared different from the unstressed solution stability study performed on different pHs between pH 1 and 7. Neither was there any obvious correlation between the degradation patterns obtained after the stressed thermal- and photostability studies performed on the drug substance in solid-state. The salt of AZ3411 fulfils basic requirements for further development of an oral immediate release (IR) dosage form, although the compound displays signs of light sensitivity and there may be a risk of solid-state transitions during formulation development and long-term storage.
AZ3411 被选为治疗炎症性肠病(IBD)的先导化合物。本研究旨在对这种 NK 拮抗剂候选药物进行早期药物评估,重点是评估具有挑战性的固态部分。X 射线粉末衍射(XRPD)、热台 XRPD 和显微镜、差示扫描量热法、热重分析测量、核磁共振波谱和液相色谱分析用于表征 AZ3411。AZ3411 的无定形游离碱形式通过使用马来酸形成盐转化为低结晶材料。在各种溶剂中制备的低结晶形式(A型)的混悬液在储存时发生相转变。一些沉淀被鉴定为 AZ3411 的马来酸盐的新的更结晶形式(B 型)。此外,在高温下观察到第三种结晶形式(C 型)。AZ3411 马来酸盐 A、马来酸盐 B 和无定形游离碱形式在 40°C/75%相对湿度(RH)、60°C 和 80°C 下储存三个月。在所有条件下,B 型被发现最稳定。在 40°C/75%RH 下储存三个月后,A 型和 B 型均转化为无水 C 型。此外,B 型在 60°C 和 80°C 下转化为 C 型,而 A 型保持不变。这些结果以及随温度丧失水分表明 B 型是水合物。水合 B 型和无水 C 型之间的相对稳定性取决于湿度和温度。此外,已经在三种不同的光照条件下研究了马来酸盐 A、马来酸盐 B 和无定形游离碱的光敏感性。与之前的研究相似,B 型是最稳定的形式。然而,在完成研究后,在最高能量条件下(765 W/m,250-800nm),结晶 B 型转化为 C 型,而 A 型失去结晶度。在 pH 1 和 pH 7 下进行了类似的光稳定性研究。两种 pH 值的降解模式相似,但与不同 pH 值之间进行的非应激溶液稳定性研究不同。在固态下进行的药物热和光稳定性应激研究后获得的降解模式之间也没有明显的相关性。尽管该化合物显示出光敏感性迹象,并且在制剂开发和长期储存过程中可能存在固态转变的风险,但 AZ3411 的盐符合进一步开发口服即时释放(IR)剂型的基本要求。